- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Post-discharge Care Plans Promote Use of Primary Care
Providing a solid base of primary-care service and coordinating specialty care for high-risk patients has been advocated as a method of lowering overall healthcare costs. Doing so would presumably reduce repeat hospitalization and emergency department visits.
Providing a solid base of primary-care service and coordinating specialty care for high-risk patients has been advocated as a method of lowering overall healthcare costs. Doing so would presumably reduce repeat hospitalization and emergency department visits. A new study in JAMA Internal Medicine suggests that such an approach does, indeed, work.
Researchers with University of Pennsylvania Perelman School of Medicine found that when low-income uninsured or Medicaid beneficiary patients at two Philadelphia hospitals were assisted by community health workers in developing an individual recovery plan, they were more likely to have a primary-care visit within 14 days of discharge and to report high-quality post-discharge communication.
Recently, research from the CMS Innovation Center received criticism for its lack of scientific rigor, but the University of Pennsylvania study was a randomized trial in which 222 patients received an individualized discharge plan from community health workers between April 10, 2011, and Oct. 30, 2012, and 224 who did not during that period.
Read the full story here: http://bit.ly/1h7RsCp
Source: Modern Healthcare
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
